Literature DB >> 1314692

Prognostic importance of human papillomavirus type 16 DNA in cervical cancer.

F Girardi1, P Fuchs, J Haas.   

Abstract

Human papillomavirus (HPV) type 16 DNA is frequent in invasive cervical cancers. Among 43 patients with invasive cervical cancer, HPV-16-positive tumors spread to the parametrial and pelvic lymph nodes significantly more often than did HPV-16-negative tumors (P less than 0.05). Demonstration of HPV-16 DNA in invasive cervical cancers may be an additional prognostic factor for this disease.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1314692     DOI： 10.1002/1097-0142(19920515)69:10<2502::aid-cncr2820691019>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  4 in total

1.  Human papillomavirus DNA and p53 status in stage IB bulky cervical cancer.

Authors:  C A Chen; T M Chen; C C Wu; C F Chang; C Y Hsieh
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

2.  Metastatic conversion of cells by expression of human papillomavirus type 16 E6 and E7 genes.

Authors:  L Chen; S Ashe; M C Singhal; D A Galloway; I Hellström; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

3.  Comparison of real-time PCR signal-amplified in situ hybridization and conventional PCR for detection and quantification of human papillomavirus in archival cervical cancer tissue.

Authors:  Karin Biedermann; Nadia Dandachi; Maria Trattner; Georgia Vogl; Hildegard Doppelmayr; Elena Moré; Alfons Staudach; Otto Dietze; Cornelia Hauser-Kronberger
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

4.  Human papillomavirus types 16 and 18 and the prognosis of patients with stage I cervical cancer.

Authors:  Rossana de Araújo Catão Zampronha; Ruffo Freitas-Junior; Eddie Fernando Candido Murta; Márcia Antoniazi Michelin; Aline Almeida Barbaresco; Sheila Jorge Adad; Amaurillo Monteiro de Oliveira; Amanda B Rassi; Glória Jabur Bittar Oton
Journal:  Clinics (Sao Paulo)       Date:  2013-06       Impact factor: 2.365
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.